Scholarlink

Background <p>To explore the abnormal expression of miR-22-5p in the serum of breast cancer (BC) patients and its clinical significance, and to clarify the potential mechanism of action.</p> Methods <p>A total of 130 female breast cancer patients diagnosed by 18&#xa0;F-FDG PET-CT and surgical pathology, along with 130 healthy female controls, were enrolled. Real-time quantitative polymerase chain reaction was used to detect serum miR-22-5p expression. Receiver Operating Characteristic curve analysis was applied to evaluate the diagnostic potential of miR-22-5p in BC. A dual-luciferase reporter gene assay was performed to validate the targeting of the MAS1 gene by miR-22-5p.</p> Results <p>Serum miR-22-5p expression was significantly higher in BC patients than in healthy controls, and positively correlated with clinical stages (III/IV vs. I/II, <i>p</i> &lt; 0.001). ROC curve analysis showed an AUC of 0.887 for diagnostic efficacy. miR-22-5p expression exhibited positive correlations with PET/CT metabolic parameters and serum tumor markers. Cell-based experiments confirmed that miR-22-5p directly targeted the 3’-UTR of the MAS1 gene, suppressing MAS1 mRNA expression. Knockdown of miR-22-5p inhibited the proliferation, migration, and invasion of BC cells, whereas concurrent suppression of MAS1 reversed these inhibitory effects.</p> Conclusions <p>Serum miR-22-5p emerges as a potential biomarker for BC diagnosis, participating in tumor metabolism and progression by regulating the MAS1 gene. This finding provides a novel therapeutic direction for BC targeted therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abnormal expression of miR-22-5p in breast cancer patients and its correlation with 18 F-FDG PET/CT features and serum-related tumor markers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Tingting Hu,
  • Pengzhou Tang,
  • Xiaoyan Wu

摘要

Background

To explore the abnormal expression of miR-22-5p in the serum of breast cancer (BC) patients and its clinical significance, and to clarify the potential mechanism of action.

Methods

A total of 130 female breast cancer patients diagnosed by 18 F-FDG PET-CT and surgical pathology, along with 130 healthy female controls, were enrolled. Real-time quantitative polymerase chain reaction was used to detect serum miR-22-5p expression. Receiver Operating Characteristic curve analysis was applied to evaluate the diagnostic potential of miR-22-5p in BC. A dual-luciferase reporter gene assay was performed to validate the targeting of the MAS1 gene by miR-22-5p.

Results

Serum miR-22-5p expression was significantly higher in BC patients than in healthy controls, and positively correlated with clinical stages (III/IV vs. I/II, p < 0.001). ROC curve analysis showed an AUC of 0.887 for diagnostic efficacy. miR-22-5p expression exhibited positive correlations with PET/CT metabolic parameters and serum tumor markers. Cell-based experiments confirmed that miR-22-5p directly targeted the 3’-UTR of the MAS1 gene, suppressing MAS1 mRNA expression. Knockdown of miR-22-5p inhibited the proliferation, migration, and invasion of BC cells, whereas concurrent suppression of MAS1 reversed these inhibitory effects.

Conclusions

Serum miR-22-5p emerges as a potential biomarker for BC diagnosis, participating in tumor metabolism and progression by regulating the MAS1 gene. This finding provides a novel therapeutic direction for BC targeted therapy.